{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:56:26Z","timestamp":1783770986081,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajogmfm.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics & Gynecology MFM"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ajogmf.2022.100658","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T12:44:24Z","timestamp":1652186664000},"page":"100658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"4","author":[{"given":"Rupsa C.","family":"Boelig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariavittoria","family":"Locci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Saccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Gragnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Berghella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajogmf.2022.100658_bib0001","first-page":"1","article-title":"Births: final data for 2018","volume":"68","author":"Martin","year":"2019","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0002","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa035140","article-title":"Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate","volume":"348","author":"Meis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0003","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1097\/AOG.0000000000004479","article-title":"Prediction and prevention of spontaneous preterm birth: ACOG Practice Bulletin, Number 234","volume":"138","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0004","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajog.2012.03.010","article-title":"Progesterone and preterm birth prevention: translating clinical trials data into clinical practice","volume":"206","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0005","unstructured":"Society for Maternal-Fetal Medicine. SMFM Statement: response to EPPPIC and considerations of the use of progestogens for the prevention of preterm birth. Online. https:\/\/www.smfm.org\/publications\/383-smfm-statement-response-to-epppic-and-considerations-of-the-use-of-progestogens-for-the-prevention-of-preterm-birth. Accessed May 5, 2022"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0006","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0039-3400227","article-title":"17-OHPC to prevent recurrent preterm birth in singleton gestations (PROLONG study): a multicenter, international, randomized double-blind trial","volume":"37","author":"Blackwell","year":"2020","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0007","unstructured":"Preterm labour and birth | Guidance | NICE; 2019. Online. https:\/\/www.nice.org.uk\/guidance\/ng25. Accessed May 20, 2022."},{"key":"10.1016\/j.ajogmf.2022.100658_bib0008","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1067\/mob.2003.41","article-title":"Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study","volume":"188","author":"Da Fonseca","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0009","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/uog.17245","article-title":"Vaginal progesterone vs intramuscular 17\u03b1-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials","volume":"49","author":"Saccone","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ajog.2015.03.031","article-title":"Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials","volume":"213","author":"Suhag","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ajog.2015.01.054","article-title":"17-Alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials","volume":"213","author":"Saccone","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0012","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.fertnstert.2016.10.031","article-title":"Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials","volume":"107","author":"Saccone","year":"2017","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0013","unstructured":"Higgins JPT, Altman DG, Sterne JAC. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration. 2011. Available at: www.cochrane-handbook.org. Accessed December 20, 2021."},{"key":"10.1016\/j.ajogmf.2022.100658_bib0014","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.fertnstert.2020.04.018","article-title":"Integrity of randomized controlled trials: challenges and solutions","volume":"113","author":"Li","year":"2020","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/aogs.12017","article-title":"Prevention of preterm birth: a randomized trial of vaginal compared with intramuscular progesterone","volume":"92","author":"Maher","year":"2013","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0016","first-page":"1301","article-title":"Comparative study of vaginal versus intramuscular progesterone in the prevention of preterm delivery: a randomized clinical trial","volume":"7","author":"Bafghi","year":"2015","journal-title":"Electron Physician"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0017","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijgo.2016.01.010","article-title":"A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth","volume":"134","author":"Elimian","year":"2016","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0018","first-page":"284","article-title":"Effectiveness of vaginal versus intramuscular progesterone for the prevention of preterm delivery","volume":"22","author":"Wajid","year":"2016","journal-title":"Int J Annals"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0019","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1080\/01443615.2018.1425380","article-title":"A randomised trial to compare 200\u2009mg micronised progesterone effervescent vaginal tablet daily with 250\u2009mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth","volume":"38","author":"Shambhavi","year":"2018","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0020","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/1471-0528.16365","article-title":"Vaginal compared with intramuscular progestogen for preventing preterm birth in high-risk pregnant women (Victoria study): a multicentre, open-label randomised trial and meta-analysis","volume":"127","author":"Choi","year":"2020","journal-title":"BJOG"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0021","doi-asserted-by":"crossref","first-page":"722.e1","DOI":"10.1016\/j.ajog.2022.02.012","article-title":"Vaginal progesterone vs intramusculuar 17-hydroxyprogesteorne caproate for prevention of recurrent preterm birth: a randomized controlled trial","volume":"226","author":"Boelig","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0022","article-title":"GRADE handbook for grading quality of evidence and strength of recommendation","author":"Schunemann","year":"2013","journal-title":"The Grade Working Group"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0023","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0024","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3109\/14767058.2012.755165","article-title":"Matched sample comparison of intramuscular versus vaginal micronized progesterone for prevention of preterm birth","volume":"26","author":"El-Gharib","year":"2013","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.mefs.2011.12.003","article-title":"Vaginal versus intramuscular progesterone in the prevention of preterm labor and their effect on uterine and fetal blood flow","volume":"17","author":"Abd El Hameed","year":"2012","journal-title":"Middle East Fertil Soc J"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0026","article-title":"Comparison the efficacy of vaginal progesterone versus 17-alpha-hydroxyprogesterone caproate to prevent preterm birth in high-risk pregnant women undergo cerclage: a randomized clinical trial","author":"Alavi","year":"2021","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0027","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/j.ajog.2016.11.700","article-title":"Comparison of vaginal and intramuscular progesterone for prevention of preterm delivery in women with a prior preterm birth","volume":"216","author":"Pasricha","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0028","article-title":"Quality criteria for randomized controlled studies: obstetrical journal guidelines","volume":"3","author":"Anderson","year":"2021","journal-title":"Am J Obstet Gynecol MFM"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0029","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(21)00217-8","article-title":"Evaluating Progestogens for Preventing preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials","volume":"397","author":"Group","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0030","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/1471-0528.15566","article-title":"Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis","volume":"126","author":"Jarde","year":"2019","journal-title":"BJOG"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0031","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1001\/jama.2017.18956","article-title":"Italian Preterm Birth Prevention (IPP) Working Group. Effect of cervical pessary on spontaneous preterm birth in women with singleton pregnancies and short cervical length: a randomized clinical trial","volume":"318","author":"Saccone","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0032","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.3109\/14767058.2015.1086742","article-title":"Omega-3 long-chain polyunsaturated fatty acids and fish oil supplementation during pregnancy: which evidence?","volume":"29","author":"Saccone","year":"2016","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0033","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40273-014-0133-2","article-title":"Cost and cost effectiveness of vaginal progesterone gel in reducing preterm birth: an economic analysis of the PREGNANT trial","volume":"32","author":"Pizzi","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0034","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1097\/AOG.0b013e31821c2d75","article-title":"Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17\u03b1-hydroxyprogesterone caproate)","volume":"117","author":"Cohen","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0035","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1016\/j.fertnstert.2010.02.033","article-title":"Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study","volume":"94","author":"Yanushpolsky","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0036","article-title":"Fetal fibronectin testing for reducing the risk of preterm birth","volume":"7","author":"Berghella","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0037","article-title":"Cervical pessary in singleton gestations with arrested preterm labor: a randomized clinical trial","volume":"3","author":"Mastantuoni","year":"2021","journal-title":"Am J Obstet Gynecol MFM"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0038","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/AOG.0000000000000668","article-title":"Omega-3 long chain polyunsaturated fatty acids to prevent preterm birth: a systematic review and meta-analysis","volume":"125","author":"Saccone","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0039","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajog.2015.03.013","article-title":"Omega-3 supplementation to prevent recurrent preterm birth: a systematic review and metaanalysis of randomized controlled trials","volume":"213","author":"Saccone","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0040","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1080\/14767058.2016.1268595","article-title":"Cervical pessary for preventing preterm birth in twin pregnancies with short cervical length: a systematic review and meta-analysis","volume":"30","author":"Saccone","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0041","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ajog.2021.02.027","article-title":"Utility of follow-up cervical length screening in low-risk women with a cervical length of 26 to 29 mm","volume":"225","author":"Boelig","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0042","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ajog.2015.09.102","article-title":"Vaginal progesterone to prevent preterm birth in pregnant women with a sonographic short cervix: clinical and public health implications","volume":"214","author":"Conde-Agudelo","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0043","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ajog.2018.03.028","article-title":"Vaginal progesterone is as effective as cervical cerclage to prevent preterm birth in women with a singleton gestation, previous spontaneous preterm birth, and a short cervix: updated indirect comparison meta-analysis","volume":"219","author":"Conde-Agudelo","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0044","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/aogs.12725","article-title":"Trends in cerclage use","volume":"94","author":"Suhag","year":"2015","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/01.AOG.0000168435.17200.53","article-title":"Cerclage for short cervix on ultrasonography: meta-analysis of trials using individual patient-level data","volume":"106","author":"Berghella","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0046","doi-asserted-by":"crossref","first-page":"h6283","DOI":"10.1136\/bmj.h6283","article-title":"Guideline Development Group. Preterm labour: summary of NICE guidance","volume":"351","author":"Sarri","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0047","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jogc.2019.04.012","article-title":"Guideline No. 398: progesterone for prevention of spontaneous preterm birth","volume":"42","author":"Jain","year":"2020","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0048","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1080\/14767058.2017.1323860","article-title":"Preterm labor and birth management: recommendations from the European Association of Perinatal Medicine","volume":"30","author":"Di Renzo","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0049","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ijgo.13852","article-title":"FIGO good practice recommendations on progestogens for prevention of preterm delivery","volume":"155","author":"Shennan","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0050","article-title":"Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth","volume":"7","author":"Dodd","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0051","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/13697137.2018.1436166","article-title":"Progestogens and pregnancy loss","volume":"21","author":"Carp","year":"2018","journal-title":"Climacteric"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0052","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ajog.2021.10.035","article-title":"In utero exposure to 17\u03b1-hydroxyprogesterone caproate and risk of cancer in offspring","volume":"226","author":"Murphy","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0053","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/AOG.0000000000001841","article-title":"A statewide progestogen promotion Program in Ohio","volume":"129","author":"Iams","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0054","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.clinthera.2015.01.007","article-title":"17\u03b1-Hydroxyprogesterone caproate access in the Louisiana Medicaid population","volume":"37","author":"Orsulak","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0055","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1080\/14767058.2018.1481035","article-title":"Utilization of progesterone and cervical length screening for prevention of recurrent preterm birth","volume":"32","author":"Boelig","year":"2019","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajogmf.2022.100658_bib0056","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ajog.2019.06.019","article-title":"Pharmacokinetics of vaginal progesterone in pregnancy","volume":"221","author":"Boelig","year":"2019","journal-title":"Am J Obstet Gynecol"}],"container-title":["American Journal of Obstetrics & Gynecology MFM"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589933322000933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589933322000933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:51:26Z","timestamp":1762905086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589933322000933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2589933322000933"],"URL":"https:\/\/doi.org\/10.1016\/j.ajogmf.2022.100658","relation":{},"ISSN":["2589-9333"],"issn-type":[{"value":"2589-9333","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics & Gynecology MFM","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajogmf.2022.100658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100658"}}